Month: September 2024

AT A GLANCE On x.com Senator Bernie Sanders said once Ozempic’s exclusivity ends, drug manufacturers could sell generic versions for less than $100 per month. Dr. Daniela Lamas writes on GLP-1 meds in The New York Times, that the drugs’ ‘…numerous benefits are pointing to an emerging cause of so much human disease: inflammation.’ Dr. Lotte Bjerre Knudsen at Novo Nordisk, who led the team that

AT A GLANCE Andrew Joseph at STAT writes from the European Society of Cardiology’s annual meeting in London, that ‘…Wegovy’s the word.’ The Peterson-KFF Health System Tracker writes ‘…over 40% of adults under 65 with private insurance could be indicated for a GLP-1 drug…’ totaling 57.4 million US adults. Quartz reports on BioAge Labs leading drug candidate azelaprag, a pill that mimics apelin, when taken with a

AT A GLANCE STAT notes ‘…Glucose tracking is the future, Dexcom executives gushed at a glitzy launch event…’ A busy week on GLP-1 pricing… first, with NBC News referring to Novo Nordisk CEO Lars Fruergaard Jorgensen defending the high cost of Ozempic and Wegovy in the U.S. Eli Lilly unexpectedly ‘…announced Zepbound 2.5 mg and 5 mg single-dose vials are available… at a 50% or greater